American Society of Hematology

Figure 1

$Figure 1. MSCs protect FLT3/ITD AML cells from FI-700- and doxorubicin-induced cell death. (A) FLT3/ITD MOLM-13 cells were treated with 800nM FI-700 (FI), 2μM Nutlin-3a (N3a), 100nM doxorubicin (Dox), 200nM AraC or left untreated and cultured for 24 hours in the presence or absence of MSCs from 3 normal subjects, and the numbers of viable cells and annexin V–positive fractions were measured. (B-C) MOLM-13 cells were treated for 72 hours with the indicated concentrations of FI-700 (B) or doxorubicin (C) in the presence or absence of MSCs, and the numbers of viable cells and annexin V–positive fractions were measured. Asterisk (*) indicates significance at P < .05.$

MSCs protect FLT3/ITD AML cells from FI-700- and doxorubicin-induced cell death. (A) FLT3/ITD MOLM-13 cells were treated with 800nM FI-700 (FI), 2μM Nutlin-3a (N3a), 100nM doxorubicin (Dox), 200nM AraC or left untreated and cultured for 24 hours in the presence or absence of MSCs from 3 normal subjects, and the numbers of viable cells and annexin V–positive fractions were measured. (B-C) MOLM-13 cells were treated for 72 hours with the indicated concentrations of FI-700 (B) or doxorubicin (C) in the presence or absence of MSCs, and the numbers of viable cells and annexin V–positive fractions were measured. Asterisk (*) indicates significance at P < .05.

This Feature Is Available To Subscribers Only